# CRISPR Gene Therapy Shows 97% Success Rate in Long-Term Sickle Cell Trial - Date: 2026-03-12 A CRISPR-based gene therapy continues showing remarkable results for patients with sickle cell disease, according to data published in the New England Journal of Medicine. Casgevy (exagamglogene autotemcel), the first FDA-approved therapy developed using CRISPR gene-editing technology, achieved ... ---